• Johnson & Johnson (NYSE:JNJ) reported multiple milestone clinical trial readouts at ASCO 2026 across autoimmunity, oncology, and myeloma.
• The company highlighted first in class efficacy signals for FcRn-blocker nipocalimab in systemic lupus erythematosus (SLE) and promising outcomes in Sjögren's disease.
• Phase 3 data for prostate cancer and myeloma therapies were described as practice changing in scope, with potential to influence future treatment standards and regulatory plans.

For investors watching NYSE:JNJ, these clinical updates add fresh detail to the story behind a stock currently trading at $232.77. Over the past year the shares are up 53.9%, with a 12.3% gain year to date and positive returns of 3.3% over 7 days and 3.6% over 30 days. The company is putting more clinical substance behind those price moves with data that stretches across several high unmet need areas.

Looking ahead, the key questions for readers are how quickly Johnson & Johnson can turn these ASCO 2026 data into regulatory filings, label expansions, and eventual commercial products. The breadth of results in SLE, Sjögren's disease, prostate cancer, and myeloma could be important as you assess how different parts of the pipeline might influence segment mix, risk profile, and the longer term story around NYSE:JNJ.

Stay updated on the most important news stories for Johnson & Johnson by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Johnson & Johnson.

Investor Checklist

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$232.77, JNJ trades about 7.9% below the US$252.87 analyst target, sitting inside the usual 10% "fair" band.
• ✅ Simply Wall St Valuation: Simply Wall St flags the stock as trading around 37.8% below its estimated fair value.
• ✅ Recent Momentum: The 30 day return of 3.6% shows positive short term momentum as the ASCO story lands.

There is only one way to know the right time to buy, sell or hold Johnson & Johnson. Head to Simply Wall St's company report for the latest analysis of Johnson & Johnson's Fair Value..

Key Considerations

• 📊 The ASCO 2026 data reinforces Johnson & Johnson's pipeline across autoimmunity and oncology. This sits on top of an existing P/E of 26.6 and analyst coverage pointing to a US$252.87 target.
• 📊 Watch the timing of regulatory filings, future readouts for nipocalimab in SLE and Sjögren's disease, and any updates on commercialization plans for the prostate cancer and myeloma therapies.
• ⚠️ Simply Wall St flags one minor risk related to a high level of debt, which is worth monitoring if more capital is needed to support these programs.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Johnson & Johnson analysis. Alternatively, you can check out the community page for Johnson & Johnson to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.